-
First-trimester markers of aneuploidy in women positive for HIV.
Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
BJOG 2011;118:844-8. -
A mixture model of nuchal translucency thickness in screening for chromosomal defects.
Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:376-83. -
Detection of circulating fetal cells utilizing automated microscopy: potential for noninvasive prenatal diagnosis of chromosomal aneuploidies.
Seppo A, Frisova V, Ichetovkin I, Kim Y, Evans MI, Antsaklis A, Nicolaides KH, Tafas T, Tsipouras P, Kilpatrick MW.
Prenat Diagn 2008;28:815-21. -
Learning curve for Doppler assessment of ductus venosus flow at 11 + 0 to 13 + 6 weeks' gestation.
Maiz N, Kagan KO, Milovanovic Z, Celik E, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:503-6. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
Aberrant right subclavian artery at 11 + 0 to 13 + 6 weeks of gestation in chromosomally normal and abnormal fetuses.
Borenstein M, Cavoretto P, Allan L, Huggon I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:20-4. -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Increased fetal nuchal translucency at 11-14 weeks.
Nicolaides KH, Heath V, Cicero S.
Prenat Diagn 2002;22:308-15. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks.
Bindra R, Heath V, Nicolaides KH.
Clin Obstet Gynecol 2002;45:661-70.